Source: Annual Congress 2005 - Monitoring response to treatment in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. L. Dente, A. DiFranco, A. DiPaco, E. Garbella, B. Vagaggini, M. DeSantis, P. Paggiaro (Pisa, Italy). Decline of FEV₁ in different groups of severe refractory asthmatics. Eur Respir J 2005; 26: Suppl. 49, 3686

Member's Comments

No comment yet.

Related content which might interest you: Changes in FEV1 and SpO2 in patients with severe and very severe COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 What are the differences between moderate and severe COPD exacerbation groups? Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma Source: International Congress 2017 – Asthma management Year: 2017 Evaluation of the individual bronchodilator response in patients with severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020 Exacerbation frequency and FEV1 decline of COPD: is it geographic? Source: Eur Respir J 2014; 43: 1220-1222 Year: 2014 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020